Rhubarb-Derived drug could tackle fatty liver

NCT ID NCT07199933

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether diacerein, a drug made from a compound found in rhubarb, can help people with metabolic fatty liver disease. About 74 adults will receive either diacerein or a placebo for 24 weeks. The main goal is to see if the drug reduces fat in the liver, measured by MRI.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

Diacerein (a derivative of rhein, the active compound in rhubarb)

What this could lead to

If successful, this could point toward a new treatment option for metabolic fatty liver disease, a condition with no approved drugs.

What could go wrong

This is a small, early-phase trial with only 74 participants. The drug may not reduce liver fat more than placebo, and side effects are possible.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MAFLD are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

metabolic dysfunction-associated steatotic liver disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••